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SUMMARY
Cells decide to proliferate or remain quiescent using signaling pathways that link information
about the cellular environment to the G1 phase of the cell cycle. Progression through G1 phase
is controlled by pRB proteins, which function to repress the activity of E2F transcription factors
in cells exiting mitosis and in quiescent cells. Phosphorylation of pRB proteins by the G1
cyclin-dependent kinases (CDKs) releases E2F factors, promoting the transition to S phase.
CDK activity is primarily regulated by the binding of CDK catalytic subunits to cyclin partners
and CDK inhibitors. Consequently, both mitogenic and antiproliferative signals exert their
effects on cell proliferation through the transcriptional regulation and ubiquitin-dependent
degradation of cyclins and CDK inhibitors.
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1 INTRODUCTION
Control of cell proliferation generally occurs during the
first gap phase (G1) of the eukaryotic cell division cycle
(see Box 1). Multiple signals, ranging from growth factors
to DNA damage to developmental cues, influence the de-
cision to enter S phase, when DNA is replicated (Fig. 1).
Hence, G1 phase cell cycle control is intrinsically linked
with a diverse set of pathways controlling differentiation,
stem and progenitor cell quiescence, senescence, and re-
sponses to a variety of stresses. The decision to enter S phase
from G1 represents a point of no return that, in the absence
of stress such as DNA damage, commits cells to complete
the cell cycle and divide, and is therefore tightly controlled.
This decision is made at what is called the “restriction
point” in mammalian cells and “START” in yeast, after
which cells become largely refractory to extracellular sig-
nals and will complete S phase and proceed through a
second gap phase (G2 phase) and then mitosis. In multi-
cellular organisms, most differentiated cells exit the active
cell cycle during G1 phase and enter G0 phase, in which they
remain metabolically active for days or even years, perform-
ing specialized functions. Postmitotic nerve and skeletal
muscle cells provide good examples. Some G0 cells, such
as quiescent T cells, can be stimulated by mitogenic signals
to reenter the cell cycle.
The restriction point is primarily controlled in mam-
malian cells by the RB pathway, named after the first tumor
suppressor identified, the retinoblastoma protein (pRB)
(Weinberg 1995). pRB is a member of a highly conserved
family of proteins, encoded by a single gene in the single-
celled green alga Chlamydomonas (MAT3), Caenorhabditis
elegans (LIN-35), and Arabidopsis (RBR1); two genes in
Drosophila (RBF1 and RBF2); and three genes in mamma-
lian cells (RB1; p107, also known as RBL1; and p130, also
known as RBL2) (Weinberg 1995; van den Heuvel and
Dyson 2008). Budding yeast cells contain a protein
(Whi5) that, although it does not share sequence similarity
with pRB, functions at START in a similar manner (Cos-
tanzo et al. 2004; de Bruin et al. 2004). pRB proteins are
present as hypophosphorylated, active forms in cells exiting
mitosis and in quiescent cells, where they use a conserved
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Figure 1. G1 cell cycle control by the pRB pathway. Many cellular
signaling events are intrinsically linked to G1 phase of the cell cycle,
which is controlled by the RB pathway. Signaling to the RB pathway
and thus G1 control by different cellular processes is achieved mainly
through the regulation of cyclins and CDK inhibitors (CKIs). In
mammalian cells, mitogenic signals first induce the synthesis of
D-type cyclins, leading to activation of cyclin-D-dependent CDK4
and CDK6, and then induce E-type cyclins to activate CDK2.
Cyclin-D–CDK4/6 and cyclin-E–CDK2 cooperatively phosphory-
late RB-family proteins, derepressing E2F to allow transcription
of E2F-target genes, thereby promoting the G1/S transition. The
INK4 proteins specifically inhibit CDK4 and CDK6, whereas the
p21 (CIP/KIP) family of CKIs inhibits multiple CDKs. Although
the schematic illustration is based on mammalian cells, the regula-
tion of both G1 cyclins and CDK inhibitors is evolutionarily
conserved.
BOX 1. THE EUKARYOTIC CELL CYCLE
The classical cell cycle comprises four phases—G1, S, G2,
and M—and is controlled by cyclin-dependent kinases
(CDKs) and their cyclin partners. The commitment to divide
occurs in G1 phase, which is controlled by cyclin-D–
CDK4/6 and cyclin-E–CDK2 at the so-called G1/S transi-
tion. DNA is then replicated in S phase. This is followed by a
second gap phase, G2, at the end of which cyclin-B–CDK1
controls entry into M phase (mitosis), when the cell divides.
Cells can exit the cell cycle in G1 phase and enter G0 phase
(quiescence). In some cases, they can reenter the cell cycle
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associated proteins and transcription factors, particularly
members of the E2F family. pRB proteins negatively regu-
late the expression of E2F-target genes, many of which are
required for entry into and progression through S phase, by
recruiting various repressive chromatin regulatory com-
plexes and histone-modifying enzymes or by blocking the
transactivation function of E2F proteins. Phosphorylation
of the pRB family proteins by CDKs during G1 phase causes
pRB to dissociate from E2Fs, allowing the transcription of
target genes that stimulate progression into S phase (Fig. 1)
(Dyson 1998).
The principal kinases that phosphorylate pRB family
proteins during G1 phase in mammalian cells are three
cyclin-dependent kinases (CDKs)5: cyclin-D-dependent
CDK4 and CDK6 (Ewen et al. 1993; Kato et al. 1993) and
cyclin-E-dependent CDK2 (Akiyama et al. 1992; Hinds
et al. 1992). As many as eight distinct mammalian G1
CDK–cyclin complexes can be formed from combinatorial
association of three D-type cyclins (cyclins D1, D2, and
D3) with CDK4 and CDK6 and two E-type cyclins (cyclins
E1 and E2) with CDK2, and these phosphorylate as many
as 16 sites in pRB proteins (Akiyama et al. 1992; Kitagawa
et al. 1996). Regulation of pRB-E2F by G1 CDKs has been
evolutionarily conserved in plants, worms, flies, and mam-
mals (Inze 2005; van den Heuvel and Dyson 2008). The
complexity of the pRB pathway reflects the need to meet the
demand to integrate diverse signals from different signaling
pathways into a central G1 control mechanism. Disruption
of this mechanism results in a wide range of developmental
defects and human diseases, particularly cancer. Indeed,
disruption of G1 control probably represents a common
event in the development of most types of human cancer
(Sherr 1996).
The critical role of pRB and G1 CDKs in controlling the
G1/S transition is further illustrated by the studies of three
DNA tumor viruses: adenovirus, human papilloma virus
(HPV), and simian virus 40 (SV40). Although evolution-
arily distant from each other, these viruses encode unrelat-
ed proteins (E1A in adenovirus, E7 in HPV, and large T in
SV40) that bind to and inactivate pRB via an LxCxE motif
to promote cell proliferation and viral replication. Primate
herpesvirus saimiri and human Kaposi’s sarcoma virus en-
code cyclin D homologs (v-cyclins) that preferentially bind
to and activate CDK6, creating complexes that are resistant
to CDK inhibitors (CKIs; see below).
The steady-state levels of CDK2, CDK4, and CDK6
proteins remain relatively constant during the normal
cell cycle and in quiescent, aging, and even terminally
differentiated cells. Signaling pathways that affect G1 phase
progression thus do not affect CDK levels and instead act
mainly through regulation of CDK activity by controlling
the abundance of their cyclin partners and a group of CKIs.
Although both cyclins and CKIs can be regulated at the
level of mRNA stability, translational control, and subcel-
lular localization, the two major control mechanisms are
transcriptional regulation and ubiquitin-dependent prote-
olysis. We discuss these mechanisms below, focusing on the
regulation of expression and ubiquitylation of G1 cyclins
and CKIs by different signal transduction pathways.
2 TRANSCRIPTIONAL REGULATION OF G1
CYCLINS BY MITOGENIC SIGNALS
2.1 D-Type Cyclins
D-type cyclins were simultaneously isolated initially from
mammalian cells in a genetic screen for genes capable of
complementing G1 cyclin deficiency in yeast, as the product
of a gene whose expression is induced by colony-stimulat-
ing factor (CSF1), and as the product of the potential on-
cogene BCL1 that is clonally rearranged and overexpressed
in a subset of parathyroid tumors (Matsushime et al. 1991;
Motokura et al. 1991; Xiong et al. 1991). These findings
provided early evidence linking the activation of a G1 cyclin
with mitogenic growth factors and implicating abnormal
expression of G1 cyclins in tumorigenesis. However, subse-
quent genetic analyses revealed only a relatively minor role
of cyclin-D-dependent CDK activity in cell proliferation
and development (Meyer et al. 2000; Kozar et al. 2004;
Malumbres et al. 2004), although mouse embryonic fibro-
blasts (MEFs) from mice lacking CDK4 and CDK6 do have
a reduced rate of exiting from quiescence in response to
mitogenic stimulation. Hence, the D-type cyclins, al-
though not an obligate component of the cell cycle ma-
chinery, couple extracellular mitogenic signals to the G1/S
transition (Sherr and Roberts 2004).
The canonical Ras–Raf–MEK–ERK mitogen-activat-
ed protein kinase (MAPK) pathway is the best characterized
pathway for the activation of cyclin D transcription (Mor-
rison 2012). It stimulates the expression of AP1 transcrip-
tion factors such as the proto-oncogene products Jun and
Fos, which bind directly to an AP1 site in the cyclin D1
promoter (Albanese et al. 1995). D-type cyclins can also be
induced by other signaling pathways, including mitogen-
stimulated Rac and NF-kB signaling, cytokine signaling,
signaling by receptors for extracellular matrix (ECM) pro-
teins (e.g., integrins), and the Wnt and Notch pathways
(Kopan 2012; Nusse 2012). Multiple transcription factors
directly regulate cyclin D genes, including Jun, Fos, STAT3,
b-catenin, and NF-kB (Fig. 2A). Cyclin D genes are ex-
5CDKs are a family of kinases that regulate the cell cycle and that require
binding to noncatalytic partner proteins termed cyclins for activity.
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pressed at very low levels in most differentiated tissues, in
part because of transcriptional repression by proteins such
as Jumonji and SIP (Klein and Assoian 2008). Repression of
G1 cyclin expression is an important part of cell cycle exit
and terminal differentiation, and inappropriate reactiva-
tion of D- or E-type cyclins can drive differentiated cells
back into S phase (Buttitta et al. 2007; Korzelius et al. 2011).
In contrast to cyclin D repression, inappropriate cyclin-
D-dependent CDK4/6 activity represents the most fre-
quent alteration of human cyclins in cancer and bears clear
pathological significance. Human cyclin D1 is amplified
in an estimated 13% of neoplasms of different types, in-
cluding breast cancer, esophageal cancer, and lymphoma
(Bates and Peters 1995). Mice transgenically expressing cy-
clin D1 develop mammary gland tumors and conversely are
protected against mammary tumors if cyclin D1 is deleted
(Wang et al. 1994; Yu et al. 2001). Likewise, CDK4 and
CDK6 are also frequently amplified in diverse human can-
cers. Mouse cells lacking either combination of the three
cyclin D proteins or CDK4/6 are more resistant to onco-
genic transformation (Sherr and Roberts 2004; Malumbres
and Barbacid 2009). These observations indicate that
whereas a low level of G1 CDK activity is sufficient to sup-
port cell proliferation in response to normal physiological
levels of mitogens, significantly higher levels of G1 CDK
activity are required to sustain hyperproliferative stimula-
tion, such as those elicited by activated oncogenes.
2.2 Cyclin E Expression
Cyclin E is encoded by a single gene in C. elegans (CYE-1)
and Drosophila (CycE) and by two genes in mammalian
cells (E1 and E2). The worm and fly cyclin E genes are
essential for cell cycle progression and development (Knob-
lich et al. 1994; Fay and Han 2000). In contrast, mice
lacking both cyclin E1 and E2 or CDK2 are viable and dis-
play relatively minor defects late in development, owing to
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Figure 2. Transcriptional regulation of G1 cyclins. (A) The expression of cyclin genes is tightly regulated at the level of
transcription by different signals, including many mitogens. The figure uses human cyclin D1 as an example. (B)
Cyclin E expression is also highly regulated and responds to two types of developmental signals, those that are cell-
type specific and those that all cells use to control proliferation in response to their environment. MAPK, Mitogen-
activated protein kinases; ECM, extracellular matrix; STAT, signal transducers and activators of transcription; KLF,
Kruppel-like factor; CSL, CBF-1/suppressor of hairless/LAG-1; TCF, ternary complex factor; NF-kB, nuclear factor-
kB; SIP1, SMAD interacting protein 1; HH, Hedgehog; Ci, Drosophila cubitus interruptus; YKI, Yorkie.
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et al. 2003; Ortega et al. 2003; Parisi et al. 2003). In well-fed
proliferating cells, cyclin E expression is cyclical, peaking at
the G1/S transition and being low or absent at other times in
the cell cycle (Lew et al. 1991; Dulic et al. 1992; Koff et al.
1992). Conversely, MEFs lacking both cyclins E1 and E2
proliferate more slowly than normal cells and have a signifi-
cantly reduced response to mitogenic stimulation, and cy-
clin E gene expression is repressed in serum-deprived cells,
all of which suggest that cyclin E responds to growth factors
(Herrera et al. 1996; Geng et al. 2003). This regulation is
important, because forced overexpression of cyclin E can
shorten G1 phase and drive cells into S phase, in part
by causing phosphorylation of pRB family proteins (Hinds
et al. 1992; Ohtsubo and Roberts 1993; Resnitzky et al.
1994). In vivo, transgenic expression of cyclin E under the
control of the b-lactoglobulin promoter in mice results in
mammary tumorigenesis (Smith et al. 2006), and over-
expression of cyclin E is frequently observed in various hu-
man cancers and correlates with increased tumoraggression
(Hwang and Clurman 2005). Hence, tight control of the
levels of cyclin E is critically important for normal cell phys-
iology and for preventing a neoplastic cell cycle. This notion
is supported by biochemical and genetic analyses of the
regulation of cyclin E by phosphorylation and by its regu-
latory protein FBW7 (see below).
Cyclin E transcription is directly controlled by E2F
(Duronio and O’Farrell 1995; Ohtani et al. 1995; Geng
et al. 1996). Thus, one important way that signaling regu-
lates cyclin E is through the pRB/E2F pathway, which also
integrates the output from the growth factor signals that
control D-type-cyclin-dependent CDK activity. Indeed, if
the mouse cyclin E gene is engineered to respond to the
signals that control cyclin D1 gene expression, then cyclin
D1 is no longer needed (Geng et al. 1999). Because cyclin-
E–CDK2 can phosphorylate and inactivate pRB, resulting
in E2F activity, a positive feedback amplification is an im-
portant part of G1/S control (Fig. 1B). This helps produce
the switch-like behavior needed for unidirectional deci-
sions like the G1/S transition (Xiong and Ferrell 2003; Fer-
rell et al. 2009).
Control of cyclin E transcription via E2F is a corner-
stone of G1/S cell cycle control, but the cyclin E gene also
responds directly to signaling pathways. This often occurs
when developmental programs coordinate cell cycle pro-
gression with cell differentiation. In the Drosophila eye, for
example, Hedgehog signaling induces cyclin E at the G1/S
transition of the last cell cycle before differentiation of spe-
cialized cell types such as photoreceptors (Ingham 2012).
The Drosophila CycE gene contains multiple enhancer ele-
ments that respond to and integrate various signals (Fig.
2B), including those from the pRB/E2F, Hedgehog and
Wnt signaling pathways, in different cell types at different
stages of development (Jones et al. 2000; Deb et al. 2008;
Ingham 2012).
In Drosophila, CycE is also a target of the growth-in-
hibitory Hippo pathway (Harvey and Hariharan 2012),
whose main target is the inactivation of the transcrip-
tional coactivator Yorkie (YKI) (Huang et al. 2005). Tissue
overgrowth upon disruption of the Hippo pathway is ac-
companied by increased expression of cyclin E, probably
through direct regulation of CycE transcription by tran-
scription factors associated with YKI. In vertebrates, the
Hippo-pathway-mediated regulation of cell proliferation
appears to be largely mediated by cyclin D1 (Cao et al.
2008).
Transcription of the cyclin E gene thus responds to two
types of developmental signals: those that are cell type spe-
cific and essential for cell cycle progression (e.g., Hedgehog
and Wnt signals), and those that are not cell type specific or
strictly essential for cell cycle progression but instead mod-
ulate the rate of growth and cell proliferation in response
to the cellular environment (e.g., E2F-mediated responses
and Hippo) (Fig. 2B).
2.3 Posttranscriptional Regulation of CDKs
Posttranscriptional mechanisms also regulate CDK activity
in response to various signals. The mitotic CDK, CDK1
(also known as CDC2), is inhibited during interphase by
phosphorylation at two adjacent residues within its cata-
lytic pocket, T14 and Y15, and is activated by CDC25-me-
diated dephosphorylation to bring about a sudden burst
of CDK1 activity that triggers mitosis (Rhind and Russel
2012; Hariharan 2013). Both CDK2 and CDK4 are also
phosphorylated at analogous residues to mediate the re-
sponses to different signals: phosphorylation of T14 and
Y15 of CDK2 is important for regulating the timing of
DNA replication and centrosome duplication (Zhao et al.
2012), and phosphorylation of Y17 of CDK4 is required for
G1 arrest upon UV irradiation, which could cause DNA
damage that should be repaired before entry into S phase
(Terada et al. 1995).
3 TRANSCRIPTIONAL REGULATION OF CDK
INHIBITORS
CKIs play an important role in arresting the cell cycle in G1
phase in response to a variety of stimuli, ranging from
growth factor deprivation to DNA damage, cellular stress,
differentiation, and senescence. Failure to arrest the cell
cycle resulting from loss of function of a CKI can cause
developmental defects or hyperplasia and tumorigenesis.
The first CKI characterized was mammalian p21 (also
known as CDKN1A, CIP1, or WAF1), which binds to and
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inhibits the activity of multiple CDK–cyclin complexes
(Xiong et al. 1992, 1993a; Harper et al. 1993). The p21
family (also known as the CIP/KIP family) includes three
related proteins: p21, p27 (also known as CDKN1B or
KIP1), and p57 (also known as CDKN1C or KIP2). A dis-
tinct CKI, p16 (also known as INK4A), was isolated around
the same time and is a specific inhibitor of CDK4 (Serrano
et al. 1993). p16 is the founding member of a separate
family of INK4 CKIs that includes three additional pro-
teins: p15 (also known as INK4B), p18 (also known as
INK4C), and p19 (also known as INK4D) (Sherr and Rob-
erts 1995).
These two families of CKIs inhibit CDK via different
mechanisms. The INK4 proteins bind selectively to the
catalytic subunits of two CDKs, CDK4 and CDK6, prevent-
ing cyclin binding; and the p21 CKIs bind to the cyclin–
CDK complex by contacting both subunits via different
motifs to block kinase activity and substrate binding.
CKIs of both families are localized predominantly in the
nucleus in most tissues, but p21 family CKIs have also been
frequently observed in the cytoplasm, where they have been
linked to CDK-independent functions and tumor develop-
ment. In particular, reduced nuclear p27 and accumulation
of cytoplasmic p27 have been observed in multiple types of
human cancers and are associated with poor prognosis of
breast cancer (Wander et al. 2011).
The two separate families of multiple CDK inhibitors
evolved to meet the increasing need to integrate numerous
different antiproliferative signals that can arrest cells in G1
phase. Mice lacking CKI genes have various phenotypes,
ranging from a compromised DNA damage response ( p21
mutants) to widespread hyperplastic cell proliferation and
organomegaly (p18- and p27-null mice), spontaneous tu-
mor development (p16-null mice), and perinatal lethality
and widespread developmental defects (in p57-null mice)
(Ortega et al. 2002). Furthermore, genetic studies of p21-
type CKIs in worms and flies have revealed various func-
tions from control of cell cycle progression to cell cycle exit
in specific cell types at various times in development (de
Nooij et al. 1996; Lane et al. 1996; Hong et al. 1998; Firth
and Baker 2005).
One major difference between the two CKI families is
their stability. The p21 family inhibitors are intrinsically
unstable (t1/2 , 30 min) as a result of ubiquitin-depen-
dent, and in most cases phosphorylation-promoted, pro-
teasomal degradation, and cause a rapid and transient cell
cycle arrest, for example, following DNA damage. In con-
trast, the INK4 proteins are stable (t1/2 . 4–6 h) and are
subject to minimal posttranslational regulation. INK4 pro-
teins therefore maintain a long-term or permanent cell cycle
arrest in stem, progenitor, senescent, and postmitotic cells.
Accordingly, whereas p21 family CKIs are regulated both
transcriptionally and posttranscriptionally, the INK4 mem-
bers are regulated primarily at the level of transcription.
3.1 p21 Transcription Regulation by p53-Dependent
and -Independent Mechanisms
Cells use signaling pathways to respond to a variety of ex-
ogenous and intrinsic stresses that have the potential to
damage the genome. The tumor suppressor p53 functions
as a transcription factor to activate the expression of many
genes involved in stress responses, and defects in p53-me-
diated stress responses are associated with most types of
human cancer. p53-mediated transcriptional activation
of p21 following DNA damage was the first identified ex-
ample of G1-phase regulation of a CKI gene (El-Deiry et al.
1993; Xiong et al. 1993b). Given that none of the other six
CKI genes is a direct target of p53, the p53–p21–CDK
regulatory module constitutes a major mechanism for
DNA-damage-induced cell cycle arrest. Indeed, knocking
out the p21 gene compromises the DNA damage response
despite having little effect on overall mouse development
(Brugarolas et al. 1995; Deng et al. 1995).
Transcriptional regulation of the p21 gene has also been
linked to p53-independent cell cycle exit during develop-
ment. In the Drosophila embryonic epidermis, activation of
the dacapo (dap) gene, which encodes a p21-type CKI,
triggers cell cycle exit (de Nooij et al. 1996; Lane et al.
1996). In Caenorhabditis elegans, the insulin-like growth
factor signaling pathway similarly induces p21 expression
in response to starvation, which results in cell cycle arrest in
stem cells (Baugh and Sternberg 2006), and Ras/MAPK
signaling activates p21 to control cell cycle exit in vulval
precursor cells (Clayton et al. 2008). This diversity of re-
sponses probably relies on the existence of multiple, mod-
ular enhancers for the p21 gene that respond to different
signaling pathways (Liu et al. 2002; Meyer et al. 2002).
3.2 INK4 Repression in Stem and Progenitor Cells
INK4 genes have distinct expression patterns during devel-
opment in adult tissues and in response to different con-
ditions (Roussel 1999). p16 is a target of Polycomb group
(PcG) transcriptional repressors: deletion of the Polycomb
gene Bmi1 retards cell proliferation, and this is associat-
ed with up-regulation of p16 and can be partially rescued
by deletion of p16 (van Lohuizen et al. 1991; Jacobs et
al. 1999). Furthermore, both PcG repression complexes
(PRC1 and PRC2) collaborate with pRB proteins to bind
to the p16 locus and trimethylate histone H3 lysine 27
(H3K27) to repress the expression of p16 (Bracken et al.
2007; Kotake et al. 2007). These findings explain how the
up-regulation of p16 in aging stem cells results from de-
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creased expression of Polycomb genes and reveal a nega-
tive-feedback loop between p16 and pRB.6 In many differ-
ent types of human tumors, p16 expression is silenced by
promoter DNA methylation (Merlo et al. 1995).
Unlike p16 mRNA, which is undetectable in young tis-
sues and is induced during aging, p18 mRNA is present
early in embryogenesis and maintains a high level through-
out life in many adult tissues (Zindy et al. 1997). Deletion
of p18 in mice results in spontaneous development of var-
ious tumors (Franklin et al. 1998; Pei et al. 2009) and in-
creases self-renewing division of hematopoietic stem cells
and expansion of mammary luminal progenitor cells (Yuan
et al. 2004; Pei et al. 2009). p18 thus seems to suppress
tumorigenesis by maintaining a quiescent state in stem
and progenitor cells of different organs. GATA3, a tran-
scription factor specifying mammary luminal cell fate,
binds to the p18 locus and represses p18 transcription
(Pei et al. 2009). It provides an example of a lineage-spec-
ifying factor that regulates cell differentiation in part by
repressing the expression of an INK4 gene to allow quies-
cent progenitor cells to exit G0/G1 arrest, reenter the cell
cycle, and proliferate.
4 CONTROL OF G1 CYCLINS BY THE UBIQUITIN–
PROTEASOME SYSTEM
Like their mitotic counterparts (Hariharan 2013), G1 cy-
clins undergo rapid turnover and are degraded by the ubiq-
uitin–proteasome pathway. This process is tightly regulated
through the phosphorylation of cyclins and, in some cases,
by proteins that target cyclins to E3 ubiquitin ligases, which
provide mechanisms for extracellular factors to signal to the
G1-phase cell cycle control machinery.
The level of cyclin E, and associated CDK2 activity,
oscillates during the cell cycle (Dulic et al. 1992; Koff
et al. 1992). Cyclin E begins to accumulate during the mid-
dle of G1 phase (as a result of E2F-mediated transcriptional
activation), peaks at the G1/S transition, and then is de-
stroyed during S phase following ubiquitylation. FBW7
(also known as Cdc4 or Ago) is an F-box protein that is
the substrate-recognition component of the E3 ubiquitin
ligase SCF (also known as CRL1) and recognizes two phos-
phodegrons in cyclin E: a carboxy-terminal degron cen-
tered on T380 and an amino-terminal degron centered
on T62 (Fig. 3) (Welcker and Clurman 2008). Both cyclin
E degrons are phosphorylated by GSK3 and CDK2 itself,
creating two independent FBW7-binding sites. Cyclin-E–
CDK2 is thought to phosphorylate cyclin E first at T384,
creating a “priming phosphate” that is needed for GSK3 to
phosphorylate T380 upstream, thus generating the doubly
phosphorylated phosphodegron that is specifically recog-
nized by the FBW7 targeting subunit of SCF-FBW7.
Because GSK3 plays critical roles in diverse signals, in-
cluding those activated by insulin, mitogenic growth fac-
tors, Wnts, Hedgehog, and cytokines, GSK3 activity can
link the regulation of cyclin E and thus G1 progression
to different signaling pathways. For example, GSK3 is reg-
ulated by the phosphoinositide 3 kinase (PI3K)–AKT
pathway, which allows a major mitogen signaling pathway




















Figure 3. Targeting ubiquitin-dependent degradation of cyclin E. F-
box protein FBW7 specifically recognizes two separate phosphode-
grons in cyclin E and targets cyclin E for ubiquitin-dependent pro-
teasome degradation by the SCF-FBW7 E3 ligase complex. The
phosphorylation of both amino- and carboxy-terminal degrons in
cyclin E is catalyzed by GSK3 and CDK2 and creates two separate
binding sites for FBW7. Both mitogenic and antiproliferative sig-
nals exert their effect on the cell cycle through cyclin E ubiquitylation
by inhibiting the activity of GSK3 or stimulating the expression of
FBW7, respectively.
6Linked to p16, both structurally in the genome and through regulation by
Polycomb group proteins, is the product of the ARF tumor suppressor gene,
which is transcribed from an alternative promoter and translated in an al-
ternative reading frame from p16. ARF does not share any amino acid se-
quence similarity with INK4 proteins and instead acts as a p53 activator by
binding to and inhibiting the activity of MDM2, the principle E3 ubiquitin
ligase for and negative regulator of p53. As a result, any signal, such as
oncogenic stimulation, that induces the expression of ARF will stabilize
p53 and activate p21, leading to G1 cell cycle arrest.
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Transgenic expression of mutant cyclin E (T380A) in mam-
mary glands causes more widespread hyperplasia than that
of wild-type cyclin E and promotes p53 loss of heterozy-
gosity and tumorigenesis (Smith et al. 2006). Knock-in
mutations that ablate both T62 and T380 result in disrup-
tion of cyclin E periodicity, increased cyclin E activity, and
abnormal proliferation in multiple cell types (Minella et al.
2008).
Studies of Fbw7-mutant mice and loss-of-function mu-
tations of FBW7 in human cancer support a role for SCF-
FBW7 in negative regulation of cell proliferation by target-
ing cyclin E, as well as Myc, Notch, and Jun (Welcker and
Clurman 2008). Mitogen signaling can also influence the
activity of FBW7 itself. In mammalian cells, activated Ras
increases cyclin E levels by inhibiting binding of cyclin E
to FBW7 (Welcker and Clurman 2008), and Notch and
Hedgehog signaling suppresses cyclin E accumulation by
inducing FBW7 expression in Drosophila eye imaginal discs
(Nicholson et al. 2011). Therefore, both oncogenic and
developmental signals can control the level of cyclin E pro-
tein by regulating components of the E3 ubiquitin ligase
that targets cyclin E for destruction (Fig. 3).
Cyclin D is phosphorylated at T286, a site analogous
to T380 in cyclin E, and T286 phosphorylation promotes
cyclin D destruction (Diehl et al. 1998). Multiple F-box
proteins, such as Fbxo41, Fbxw8, SKP2, and Fbxo31,
have been implicated in targeting cyclin D for destruction,
but the E3 ligase responsible remains to be definitively
identified (Kanie et al. 2012). Promoting the destruc-
tion of both D- and E-type G1 cyclins by GSK3-mediated
phosphorylation, however, could allow cells to effectively
couple the PI3K–AKT pathway to G1 cell cycle control.
T286-phosphorylated cyclin D1 can also be recognized
and stabilized in the nucleus by Pin1, a prolyl isomerase
that regulates the function of proteins by causing confor-
mational change of their S/T-phosphorylated forms (Liou
et al. 2002).
Progression through G1 phase is also controlled by
other E3 ligases. In particular, the anaphase-promoting
complex (APC), which promotes the ubiquitin-dependent
proteasomal degradation of multiple mitotic regulatory
proteins, remains active in G1 phase to suppress accumu-
lation of mitotic cyclins until cyclin-E–CDK2 is activated
at the G1/S transition.
5 CONTROL OF G1 CDK INHIBITORS BY THE
UBIQUITIN–PROTEASOME SYSTEM
Some CKIs are also regulated by the ubiquitin–proteasome
pathway. Again, this regulation involves phosphorylation of
these CKIs, which provides a mechanism linking extracel-
lular signaling to the G1 cell cycle control machinery.
5.1 Phosphorylation-Dependent Ubiquitylation
and Degradation of a Yeast CKI
In Saccharomyces cerevisiae, a single CDK, Cdc28, forms
multiple B-type cyclin–CDK complexes to drive both S
phase and mitosis. Cdc28 is inhibited by Sic1, a CKI that
is unrelated in sequence to either the p21 or INK4 family of
CKIs. Sic1 is targeted for ubiquitylation (Fig. 4) following
phosphorylation by the G1 cyclin–CDK complex Cln–
Cdc28 (Schwob et al. 1994). Inactivation of Sic1 rescues
the inviability of yeast cells lacking the G1 cyclins Cln1,
Cln2, and Cln3 (Schneider et al. 1996), and mutation of
CDK phosphorylation sites in Sic1 causes stabilization of
Sic1 and blocks DNA replication. These observations indi-
cate that the primary function of these three G1 cyclins,
once mitogenically activated, is to promote Sic1 ubiquity-
lation to bring about the G1/S transition. Phosphorylated,
but not unmodified, Sic1 binds to the F-box protein Cdc4,
which, through a linker protein, Skp1, brings Sic1 to the
Cul1 (also known as Cdc53)–Roc1 (also known as Rbx or
Hrt1) E3 ligase complex for ubiquitylation by the E2 en-
zyme Cdc34 (Feldman et al. 1997; Skowyra et al. 1997).
Nine sites in Sic1 are phosphorylated, and each contributes
to Cdc4 binding, with any six being required (Nash et al.
2001). This multisite phosphorylation requirement makes
Sic1 ubiquitylation ultrasensitive to the level of G1 CDK
activity, enabling cells to measure the strength of mitogens
and set the level of CDK activity that determines the timing
of DNA replication. It transforms a gradual accumulation
process, such as protein synthesis during G1 phase, into an
irreversible switch for the onset of DNA replication. Sic1 is
also phosphorylated by its target, the B-type cyclin–CDK
complex Clb5–CDK1, which may ensure irreversibility
of the G1/S transition once DNA replication has been
initiated.
In response to mating pheromones, budding yeast cells
arrest their cycle in G1 phase and fuse cytoplasms and nu-
clei to generate a diploid cell. This G1 cell cycle arrest is
regulated by the Fus3 MAPK pathway, which leads to phos-
phorylation and activation of Far1, a second budding yeast
CDK inhibitor that is unrelated to Sic1 and other CKIs in
sequence. Far1 selectively inhibits G1 cyclin–Cdc28, lead-
ing to the inhibition of Cln–Cdc28-induced Sic1 degrada-
tion and G1 arrest.
The distantly related fission yeast, Schizosaccharomyces
pombe, contains a single CKI, Rum1, that is unrelated to
Sic1, p21, or INK4 CKIs in sequence. Rum1 inhibits the
cyclin B–CDK complex Cdc13–Cdc2 and is an essential
G1 regulator whose deletion causes premature S-phase
initiation immediately after mitosis (Correa-Bordes and
Nurse 1995). Rum1 is degraded following ubiquitylation
by the SCF-Pop1 ligase, which uses Pop1, an ortholog of
R.J. Duronio and Y. Xiong
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budding yeast Cdc4, to target Rum1 (Kominami and Toda
1997). Hence, the mechanism for targeting G1 CDK inhib-
itors for ubiquitylation has been conserved between two
yeast species that are as evolutionarily divergent from each
other as either is from animals.
5.2 Regulation of Mammalian CIP/KIP by E3 Ligases
The mammalian CKI p27 is also regulated by ubiquitin-
dependent proteolysis (Pagano et al. 1995). p27 and its
close relative p57 are phosphorylated by cyclin-E–CDK2
at analogous sites (T187 in p27 and T310 in p57), which
promotes their binding to the F-box protein SKP2 and
subsequent ubiquitylation by the SCF-SKP2 E3 ligase.
The recognition of T187-phosphorylated p27 by SKP2
requires CKS1, a small evolutionarily conserved protein
whose function is essential for yeast cell viability and nor-
mal mouse development (Fig. 3). A second p27 E3 ligase,
KIP1-ubiquitylation-promoting complex (KPC), preferen-
tially recognizes free p27 and is competed off by the
binding of cyclin-E–CDK2 (Kamura et al. 2004). Mito-
gen-stimulated cyclin E expression and thus the formation
of the cyclin-E–CDK2 complex may switch cells from
KPC-mediated degradation of p27 during early G0/G1
transitions to SCF-mediated degradation at the G1/S tran-
sition. Likewise, p57, which plays important roles in devel-
opment, is also ubiquitylated by the SCF-SKP2 E3 ligase
and a second E3 ligase, SCF-FBL12, containing FBL12.
FBL12 is induced by TGFb1 and binds only to p57, pro-
viding a mechanism for TGFb1-induced degradation of
p57, but not p27 or p21 (Kim et al. 2008a).
p21 expression oscillates twice during each cell cycle: it
is high in G1 phase, decreases during S phase, reaccumu-
lates during G2 phase, and then decreases at early mitosis.
The protein has a very short half-life (,30 min) and is
rapidly turned over by ubiquitin-dependent proteolysis.
Several E3 ligases can target p21 ubiquitylation at different
phases of the cell cycle in both phosphorylation-dependent
and phosphorylation-independent manners. During G1






























Figure 4. Targeting ubiquitin-dependent degradation of CDK inhibitors. The p21 family of CKIs is regulated by the
ubiquitin–proteasome pathway. In many cases, this involves phosphorylation of these CKIs. Phosphorylated CKIs
are recognized by F-box proteins such as Cdc4 in budding yeast or SKP2 in human cells, which, through the SKP1
linker protein, recruits the CKI substrate to the SCF E3 ligase for ubiquitylation.
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togenic stimuli such as epidermal growth factor (EGF)
results in T57 and S130 phosphorylation on p21, leading
to its ubiquitin-dependent degradation (Fig. 3) (Hwang
et al. 2009). During S phase, WD40 protein CDT2 and
the F-box protein SKP2 target p21 for ubiquitylation by
the CRL4-CDT2 and SCF-SKP2 E3 ligases to prevent DNA
rereplication (Bornstein et al. 2003; Abbas et al. 2008; Kim
et al. 2008b; Nishitani et al. 2008). The SCF-SKP2-medi-
ated p21 ubiquitylation requires S130 phosphorylation by
cyclin-E–CDK2 (Bornstein et al. 2003). During early mi-
tosis, Cdc20 binds to p21 and targets it for ubiquitylation
by APC. CRL4 also targets p21 for ubiquitylation after low-
dose UV irradiation, to delay the cell cycle, allowing time
for optimal DNA repair (Bendjennat et al. 2003; Havens
and Walter 2011; Starostina and Kipreos 2012). Hence, the
mechanism for targeting G1 CKIs for ubiquitylation has
been conserved from yeast to animals and links the regula-
tion of CKI stability to signals from different pathways via
the phosphorylation of CKI proteins and their targeting
molecules.
6 CONCLUDING REMARKS
Precise cell cycle regulation is an essential aspect of normal
development and adult homeostasis. To achieve this, cells in
G1 phase integrate inputs from major cellular signaling
pathways to decide whether or not to enter S phase, which
is an irreversible cell cycle step. This integration of signals is
transformed into an appropriate level of CDK activity in
large part via changes in the level of cyclins and CKIs
achieved through the regulation of both transcription and
protein stability. One challenge for the future is to under-
stand how multiple signaling pathways cooperate to pre-
cisely regulate cyclin and CKI activity in various cell types,
particularly stem cells, in intact tissues. Another is to use
this information to develop novel therapeutics for the treat-
ment of cancer, which arises in part because of disruptions
to signaling pathways that affect cell cycle regulation.
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